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Abstract 
During the manufacture of the chemotherapeutic enzyme Erwinia chrysanthemi L- 
asparaginase, a small proportion (approximately 5 – 15%) of acidic variants, including 
deamidated species, are observed. Although the deamidated forms appear to have similar 
specific activity and quaternary structure to the unmodified enzyme, monitoring and 
control of these forms is important from a regulatory perspective. The extent of Asn to 
Asp deamidation directly correlates with the time taken to thaw the Erwinia cells. Erwinia 
L-asparaginase is a tetrameric enzyme containing one site, Asn281, theoretically very labile 
to deamidation due to the sequence Asn-Gly. The location of this part of the protein 
sequence is completely buried inside the tetramer, but solvent-exposed upon tetramer 
dissociation. During the cell thawing and alkaline lysis sequence of the process, 
lengthening the cell thaw times by up to 24h allowed tetramer to reassociate, protected 
Asn281 from deamidation and reduced the acidic species content of the L-asparaginase 
from approximately 17% to 9% as measured by weak cation-exchange (WCX) HPLC. 
The correlation of cell thaw time with acidic species content was also confirmed using 
capillary zone electrophoresis (CZE) and peptide mapping. These studies demonstrate 
that cell thaw time is an important, if unexpected, control variable for L-asparaginase 
deamidation. 
Keywords: deamidation; L-asparaginase; Erwinia; cell freeze/thaw; tetramer; capillary 
electrophoresis 
1. Introduction
L-asparaginase is an important chemotherapeutic enzyme used for the treatment of acute 
lymphoblastic leukaemia (ALL) [1]. It functions by depriving leukaemic cells of Asn, an 
amino acid which is essential for their growth and proliferation by conversion to Asp [2]. 
Commercially, the enzymes available for clinical use are Escherichia coli L-asparaginase 
(EcA) and Erwinia chrysanthemi L-asparaginase (ErA). Presently EcA is used in a 
majority of patients, but some patients develop a hypersensitivity to EcA, in which case 
ErA is utilised [3,4]. 
The proprietary name of ErA for clinical use is Erwinase® or Erwinaze®. ErA exists as a 
140,000Da homotetramer in its active form, and has an isoelectric point of pH 8.6 [5]. 
Erwinase® was first developed in the late 1960s and 1970s [6,7] and is marketed in many 
countries around the world. 
As a part of an on-going process understanding programme for ErA manufacture, a 
number of sensitive analytical characterisation techniques have been developed. These 
techniques have been validated and subsequently utilised to confirm the process 
robustness and the product quality of ErA. Monitoring of product variants, such as 
deamidated and oxidised forms of the protein, is an important part of process and product 
characterisation. Although deamidated variants of ErA appear to retain their activity and 
function, characterisation of them is nonetheless important from a regulatory perspective. 
Deamidation is one of the most frequent non-enzymatic degradation reactions to occur in 
proteins and peptides [8] and is most common in Asn residues but is also possible in Gln 
and others. In a deamidation reaction involving an Asn residue, the α-nitrogen C-terminal 
to the Asn attacks the Asn side-chain carboxylate group, resulting in a cyclic succinimide 
and evolution of ammonia. The cyclic succinimide intermediate is then hydrolysed to 
form a mixture of Asp and isoAsp [9]. Completion of the reaction leads to a lowering of 
the protein pI due to the change in residue charge from neutral to negative. This causes 
charge heterogeneity in protein products and creation of acidic protein species. 
Deamidation in protein biopharmaceuticals is undesirable, as deamidation at certain sites 
may lead to loss of secondary structure, tertiary structure, protein function, and/or enzyme 
activity [10,11]. 
Deamidation in L-asparaginase was first observed for EcA using isoelectric focusing in 
the 1970s [12,13], where it was noted that the change in isoelectric point (pI) had no 
apparent effect on enzyme activity. Deamidation of EcA was also studied by other 
researchers [14] who investigated deamidated forms using electrophoresis and amino acid 
analysis. More recently, researchers have used two-dimensional gel electrophoresis to 
separate post-translationally modified forms (including deamidated forms) of EcA and 
ErA [15]. 
The purpose of the work described in this paper was to further understand the design space 
of the ErA manufacturing process, by linking process conditions to the extent of protein 
deamidation in the final product. We show how the tertiary and quaternary structure of 
the ErA homotetramer protects an apparently labile Asn residue from deamidation under 
normal conditions, and how dissociation of the tetramer can lead to alkali-induced 
conversion of Asn residues to Asp. 
2. Materials and Methods
Cell Thaw Experiments: 
Reagents used were obtained from Sigma (Gillingham, UK) unless otherwise indicated. 
Samples of E. chrysanthemi cell paste and associated process streams were obtained from 
the HPA Development & Production, Porton Down, UK. Frozen cell pastes, stored at - 
20°C, were thawed at room temperature and once thawed, the 24h held portion was held at 
2-8°C until further processing. The pH and conductivity during cell thaw experiments was 
adjusted using NaOH and acetic acid and pH and conductivity were monitored using a 
Jenway (Staffordshire, UK) Model 3540 meter and associated pH and conductivity probes 
and calibration standards. Resin capture was accomplished using Whatman (Maidstone, 
UK) CM32 microgranular cation exchange cellulose, and eluate concentration was 
performed using Amicon (Millipore, Watford, UK) Ultra-15 centrifugal filter units with a 
10kDa MWCO regenerated cellulose membrane. 
Protein and Activity Assays: 
The protein content of all samples described in this work was determined using the 
technique of Lowry [16]. The asparaginase activity assay used is based on the Berthelot 
reaction and methods described in the literature [17,18]. 
Dissociation and Reassociation Experiments: 
 
Native PAGE analysis was conducted using the Blue Native (BN) technique developed by 
Schägger and von Jagow [19] with Invitrogen™ (Paisley, UK) Novex™ 4 – 16% Native 
PAGE Bis-Tris gels, Novex™ Native PAGE running buffers and sample buffers, fixing in 
methanol/acetic acid, and destaining in acetic acid solution. Size-exclusion 
chromatography (SEC) was performed using TSK gel G3000SWXL column (Tosoh, King 
of Prussia, PA, USA) and a Waters HPLC workstation (Elstree, UK) in an isocratic mobile 
phase consisting of 100mM sodium chloride in pH 7.2 sodium phosphate buffer. 
 
 
 
WCX Assay: 
 
The acidic species content in process samples was monitored using a Weak Cation- 
Exchange (WCX) HPLC assay, using a Dionex ProPac WCX-10 column (Dionex, Leeds, 
UK) and a Waters HPLC workstation (Elstree, UK). The column was run using a gradient 
from 10 to 300mM sodium chloride in pH 6.2 sodium phosphate buffer and monitored at a 
wavelength of 220nm. 
 
 
 
Capillary Electrophoresis Analysis: 
 
The Capillary Zone Electrophoresis (CZE) analyses of ErA samples were performed using 
a PEREGRINE high-performance capillary electrophoresis (CE) system from deltaDOT 
(London, UK) equipped with a 512 diode array detector with detection at 214nm. Bare 
fused silica capillaries were obtained from CM Scientific (Silsden, UK). 
Peptide Mapping Assay: 
 
Peptide mapping of purified ErA samples was conducted using tryptic digest followed by 
reversed-phase UPLC. Samples were denatured for 10min at 65°C in the presence of 
Rapigest SF (Waters, Elstree, UK) in pH 7.4 phosphate buffer, cooled, then digested in pH 
7.4 phosphate buffer for 2h at 37°C using sequencing-grade trypsin (Promega, 
Southampton, UK). The digests were terminated by addition of guanidinium HCl and 
injected into an ACQUITY UPLC BEH C18 (Waters, Elstree, UK) reversed-phase 2.1 x 
150mm column with 1.7µm particle size and 130Å pore size using a Waters UPLC 
workstation. The column was run in the presence of 0.1% TFA using a gradient between 
1% acetonitrile in water and 100% acetonitrile. 
 
 
 
3.0 Results and Discussion 
 
The manufacturing process for ErA has been described previously [6,20] and comprises 
the fermentation of Erwinia chrysanthemi, alkaline cell lysis and extraction of ErA [21], 
purification of the ErA using chromatography, and formulation of the final drug product 
using lyophilisation. Between each of these major process stages, the ErA intermediates 
are held frozen, and thawed before further processing occurs. 
Freezing and thawing of ErA has been shown [22,23] to cause partial dissociation 
(approximately 40% as measured using the activity assay) of the active ErA tetramer into 
the inactive monomeric 35kDa subunits. The dissociation and subsequent loss of activity 
was reported [23] to be more severe when ErA is frozen at low temperatures (-40°C and 
lower). When ErA is frozen at -20°C, we have observed this dissociation to be less 
extensive as well as reversible, such that dissociated 35kDa monomers reassemble into the 
140kDa tetramer over a time scale of approximately 24h. This effect, which has been 
observed over the course of many years of ErA process and assay development, is 
demonstrated in Figure 1. Two samples of purified ErA were frozen, and one thawed and 
left at 2 – 8°C for 24h, the other thawed immediately before simultaneous analyses using 
both SEC and native PAGE. Disappearance of the monomeric ErA subunit (peak C by 
SEC) over the 24h time scale is observed using both techniques. Note that a small amount 
of aggregated ErA (peak A by SEC) is also observed by both techniques, and is expected 
for ErA subjected to freeze-thaw cycles [22]. 
Due to the freeze-thaw steps in the ErA manufacturing process, the ErA tetramer is 
subjected to several partial dissociation and reassociation events. The timing and 
conditions of many of the freeze/thaw steps during the purification process are such that 
near-complete reassociation into the 140kDa tetramer occurs without issue. However, 
during the lysis and extraction steps of the process, the thaw of the Erwinia cell paste is 
immediately followed by an alkaline lysis step mediated by addition of NaOH, a potential 
cause of protein deamidation. 
The susceptibility of individual asparaginyl residues in proteins to deamidation has been 
shown to be influenced by primary and secondary structure. The amino acid residue C- 
terminal to Asn has been shown to be particularly important, with proteins and peptides 
that have the sequence Asn-Gly showing the highest rates of deamidation, up to 70-fold 
more than other sequences [24]. Furthermore, the secondary structure has been 
investigated with respect to deamidation rates, with both α-helical and β-sheet structures 
conferring some protection against nonenzymatic deamidation [25]. NaOH has been 
shown to be particularly aggressive in peptide deamidation of the Asn-Gly sequence, with 
increased deamidation rates for 10mM NaOH at pH 12.0 [26]. The sequence of ErA 
contains one Asn with a C-terminal Gly, at Asn281  [27].  Secondary structure analysis of 
this region of the ErA molecule using UniProt shows Asn281 may be in a β-sheet structure, 
which may confer some protection against alkaline-mediated deamidation. However, 
deamidation at this site has been previously detected, but not quantified, in lyophilised 
samples of formulated ErA using two-dimensional electrophoresis and mass spectrometry 
[15]. Most importantly for Asn281, when the quaternary structure of ErA is intact, this 
residue is buried inside the tetramer complex based on published x-ray structures [28,29]. 
We used the previously-solved structure (ID 1HG1) from the worldwide Protein Data 
Bank (PDB) to show that when the enzyme dissociates into monomers, Asn281 becomes 
solvent accessible, rendering this site available for deamidation to Asp (Figure 2). 
Therefore, prior to alkaline lysis of ErA it is important to allow sufficient time post freeze- 
thaw, for dissociated monomer to reassociate into tetramer. Allowing sufficient time for 
tetramer reassociation protects Asn281, an extremely labile residue, from deamidation. 
This effect was tested by performing ErA extraction and purification at both 1/50th  and 
1/2900th of full manufacturing scale. Each 1/50th-scale purification batch was made from 
an extract lot which had been thawed pre-lysis for either 24 or 36h, representing the upper 
and lower limits of the manufacturing operating range for this parameter. In the 1/2900th- 
scale experiments, a portion of cell paste was thawed, and subdivided in half. The first 
portion was lysed immediately (0h thaw time) while the remaining paste was held at 2 – 
8ºC for 24h before alkaline lysis. The 1/2900th-scale lysates (0h and 24h) were then 
processed normally, stopping at the crude extract stage (just prior to cation-exchange 
chromatography in the full-scale process). 
The samples from both the 1/50th and 1/2900th scale experiments were analysed using a 
variety of techniques. WCX HPLC can be used to monitor the content of the acidic 
species in ErA process intermediates. The WCX results (Figure 3) show that longer cell 
paste thaw times result in lower ErA deamidated species content.   The WCX data are 
expressed as a ratio (in %) of the sum of the area of the peaks representing acidic ErA 
species (referred to as peaks C, D and E) over the area of the peak representing the 
unmodified ErA (peak F). Peaks C, D and E are known by LC-MS to consist of ErA 
species which have been deamidated at various sites, as well as other modifications (data 
not shown).   Due to the additional impurity peaks observed in WCX for crude extract 
samples, retention times for the WCX peaks C, D, E and F in the crude materials produced 
from 1/2900th-scale cell-thaw experiments were verified using purified ErA which had an
acidic species content of approximately 10%. It is important to note that the difference in 
thawing times between the laboratory-scale (0 – 24h) and full-scale (24 – 36h) data are 
solely due to the increased time necessary to thaw larger blocks of frozen materials during 
the generation of production-scale data. 
The WCX HPLC data were further confirmed by using CZE which separates proteins 
based on the mass-to-charge ratio. This technique is useful for monitoring deamidation in 
protein products as has been discussed by other investigators [30].  The CZE data (Figure 
4) for both the laboratory-scale and full-scale manufacturing data show the effect of cell
paste hold time on the appearance of acidic species, with longer hold times resulting in 
reduced acidic species content. The time values in the figures are presented as relative 
migration times (RMT), calculated by dividing each time value by the migration time of 
the main ErA peak (analogous to relative retention times in HPLC). The deamidated 
forms of ErA migrate within the capillary just after the main band, at RMT between 1.02 
and 1.09. The RMT behaviour of the deamidated forms of ErA in the CZE assay was 
confirmed (Figure 4C) using purified ErA and the method of DiDonato et al. [31] with 
incubation in 1% ammonium bicarbonate at 37°C for 24h. The location and appearance of 
several more acidic species in the RMT 1.02 – 1.09 region after NH4HCO3 treatment is 
highly indicative of deamidation. 
Although both WCX and CZE showed a link between cell thaw time and acidic species 
content, neither technique was capable of confirming the acidic species were due to 
deamidation, or the specific involvement of Asn281. Therefore, peptide mapping was used 
to confirm the location of the affected residue(s) and provide a more definitive link 
between deamidation and the acidic species results from CZE and WCX. Tryptic digest of 
ErA results in a number of fragments including tryptic fragment T33, which has the 
sequence TGNGIVPPDEALPGLVADSLNPAHAR. The peptide map of a tryptic digest 
of pure ErA results in a peak corresponding T33 at approximately 34min retention time 
closely followed by two shoulder peaks. Although the peptide map in this work has been 
run only using UV detection of the various fragments, previous work on this validated ErA 
method using mass spectrometry (LC-MS) detection has shown the 34min peak to 
correspond to the mass of T33, and the two shoulder peaks corresponding to +1 and +2Da 
variants of T33, consistent with deamidation at one or two sites (data not shown). T33 
contains two Asn residues, with Asn281 closest to the N-terminus of this peptide fragment. 
The other Asn residue, Asn299, is also buried inside the tetramer structure in native ErA, 
and is only solvent-accessible upon tetramer dissociation, like Asn281. According to the 
literature, Asn299 should be much less susceptible to deamidation than Asn281, as the 
residue immediately C-terminal to Asn299 is Pro [24]. 
Peptide maps were conducted on tryptic digests of four purified ErA samples which had 
undergone various cell thaw times during their manufacture, and therefore had differences 
in WCX acidic species content. The ErA samples were confirmed to be pure by SDS- 
PAGE prior to peptide mapping (data not shown). The UV peaks corresponding to T33 
and the +1 and +2Da variants were integrated and the results expressed as the ratio of peak 
areas of deamidated T33 species to unaffected T33. The results (Figure 5) correlate well 
with the WCX acidic species for these samples.  These results confirm that deamidation at 
Asn281 occurs and the extent of deamidation at this site is related to the Erwinia cell thaw 
time during processing. 
 
Although the acidic ErA species content varied in laboratory-produced purification 
batches, there was no correlation with specific activity (Table 1). Although no specific 
activity data are available in the literature for acidic ErA species, this finding is consistent 
with the findings for EcA [13] where the acidic species observed did not affect the overall 
activity of the enzyme preparations. It should be noted that even those preparations which 
have a long cell thaw time result in a degree of acidic species in the product as observed 
by WCX, CZE and peptide mapping, and this may be due to deamidation of Asn which 
are on the tetramer solvent-exposed surface (e.g. Asn41) or other side reactions with ErA 
residues. 
 
 
 
4. Conclusions 
 
ErA is a tetrameric enzyme which contains multiple Asn residues. A small fraction of the 
total amount of tetramer dissociates into monomeric subunits upon freezing (at -20ºC) and 
thawing. However, given approximately 24h after thawing, the dissociated 35kDa 
monomers reassemble back into 140kDa tetramers. The dissociation and subsequent 
reassociation is observed using purified enzyme and size-based analytical techniques such 
as Native PAGE and SEC. 
Analysis of ErA structure using published results and molecular structure viewing 
software shows that one Asn residue (Asn281) is theoretically very susceptible to 
deamidation due to the ErA sequence (Asn281Gly282). This part of the ErA monomer is 
normally protected from solvent exposure due to its internal location in the tetrameric 
quaternary structure. However, upon freeze-thaw, this site is exposed due to tetramer 
dissociation. 
Through a set of repeated, controlled experiments and analytical characterisation, we have 
shown that deamidation of Asn281 can be easily controlled by lengthening the time utilised 
to thaw the Erwinia cells immediately prior to the alkaline lysis step. The results of this 
study may be used to reduce the amount of process-related acidic ErA variants appearing 
in the final purified product. Allowing a longer time for the cell thaw step allows the 
small fraction of dissociated enzyme to reassemble into tetramers, protecting Asn281. The 
long cell-thaw times result in lower ErA acidic species content as measured by several 
analytical techniques, including WCX-HPLC, CZE, and peptide mapping. 
This study shows a direct link between deamidation and processing conditions at the very 
early, crude stage of manufacture. Deamidation is typically studied in pure protein 
samples, due to the difficulty of analysing this slight change in the presence of 
contaminating proteins. Often, the specific process conditions that cause deamidation and 
other degradation pathways during processing, such as oxidation, are poorly understood. 
This kind of structural approach, linking processing conditions to analytical measurements 
far downstream, may be of interest in other protein purification processes. 
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FIGURES AND TABLES 
Figure 1. Effect of time on freeze-thaw induced ErA tetramer dissociation. The main 
frame shows an SEC trace of purified ErA at 0h and 24h post-thaw time, with the 
aggregate (A), tetramer (B) and monomer subunit (C) marked on the trace. Inset figure 
shows a NativePAGE gel image of the same experiment, with the location of monomeric 
(bottom arrow), tetrameric (middle arrow) and higher-order aggregate (top two arrows) 
species indicated. Lane 1- 1µg/well at 0h post-thaw, Lane 2- 1µg/well at 24h post-thaw, 
Lane 3- 5µg/well at 0h post-thaw, and Lane 4- 5µg/well at 24h post-thaw. 
  
 
Figure 2. Three-dimensional ErA structures created using Jmol and the published PDB 
structure 1HG1 (Lubkowski, 2003). One of the four 35kDa subunits is coloured in blue, 
the other three are coloured in grey. The location of the four Asn281 residues is shown in 
orange (CPK style). Clockwise from top left: front view, left view, top view and view 
showing one subunit only. 
(A) 
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(C) 
Figure 3. Effect of Erwinia cell paste hold time on ErA acidic species content (WCX 
HPLC assay). Data are mean values with error bars indicating the range of values in the 
data set. Longer thaw times allow dissociated ErA subunits to reassemble into tetramer, 
protecting the labile residue Asn281 from deamidation during the subsequent alkaline lysis 
step. (A) Acidic species content of cell extracts from laboratory-scale cell lysis 
experiments. (B) Acidic species content of purified protein obtained from full-scale cell 
lysis. (C) Representative WCX chromatogram for laboratory-scale data showing acidic 
species peaks (C, D and E) and the main (undegraded) species (F). 
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Figure 4. CZE Electropherogram Traces Showing Effect of Erwinia cell paste hold time 
on ErA acidic species content. The absorbance data have been normalised to the 
maximum absorbance for the main ErA peak, and the time axis normalised relative to the 
migration of the main peak. The region of interest of acidic ErA variants, verified in panel 
C, is between relative migration times of 1.02 and 1.09, and is marked in panels A and B. 
(A) CZE comparison of laboratory-scale cell extracts held pre-lysis for 0h and 24h. (B) 
CZE comparison of full-scale cell extracts held pre-lysis at 24h and 36h. (C) Effect of 24h 
1% NH4HCO3 treatment at 37°C on CZE profile. The post-treatment appearance of acidic 
variants in the relative migration region of interest (1.02 – 1.09) is marked with arrows. 
Figure 5. Correlation of WCX acidic species content with deamidation content in the 
peptide fragment T33 (corresponding to amino acid sequence 
TGNGIVPPDEALPGLVADSLNPAHAR and containing the residue  Asn281)  using 
peptide mapping HPLC. The analyses were carried out on ErA samples which were 
verified to be free from other protein contaminants using SDS-PAGE. 
Table 1.  Comparison of Acidic Species Content and Specific Activity of Purified ErA 
Produced at 1/50th manufacturing scale.
Batch ID % Acidic Species by 
WCX HPLC 
Specific Activity of 
Purified Enzyme 
(U/mg Lowry 
protein) 
1 9% 971 
2 18% 1302 
3 18% 884 
4 17% 1218 
5 17% 1405 
6 11% 978 
